Faculty Articles

Title

Potential for Dipeptidyl Peptidase-4 Inhibitor and Sodium Glucose Cotransporter 2 Inhibitor Single-Pill Combinations.

ISBN or ISSN

1744-8417

Publication Title

Expert Review of Endocrinology & Metabolism

Volume

10

Issue

3

Publication Date / Copyright Date

5-1-2015

First Page

305

Last Page

317

Publisher

Taylor & Francis

DOI Number

10.1586/17446651.2015.1004311

Abstract

With prolonged duration of Type 2 diabetes mellitus, most patients need a combination of antihyperglycemic drugs to reach their target HbA1c. Evidence shows that single-pill combinations (SPCs) may increase patient satisfaction, adherence, and reduce overall health-care costs. Several SPCs containing metformin and another oral antidiabetic drug (OAD) are available on the market. Although well established in clinical practice, long-term durability and tolerability of traditional OADs can be inadequate. Dipeptidyl peptidase (DPP)-4 inhibitors and sodium glucose cotransporter (SGLT) 2 inhibitors are two newer classes of OADs that are efficacious and are less likely to induce adverse effects such as gastrointestinal reactions, hypoglycemia and weight gain when compared with metformin, sulfonylureas, and thiazolidinediones. This article describes current efficacy and safety data of DPP-4/SGLT2 inhibitor combination therapy. Pharmacokinetics, mechanism-of-action based rationale for the combination and timing of the addition of a SPC to the treatment regimen are discussed.

Disciplines

Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences

Keywords

antidiabetic drugs, combination therapy, dipeptidyl peptidase-4 inhibitors, single-pill combination, sodium glucose cotransporter 2 inhibitors, Type 2 diabetes

Peer Reviewed

Find in your library

Share

 
COinS